ADIL Key Statistics, Chart & Performance
The current stock price of ADIL is 0.213 USD. In the past month the price decreased by -3.18%. In the past year, price decreased by -74.34%.
ADIL Technical Analysis
ADIL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ADIL. ADIL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ADIL Financial Highlights
Over the last trailing twelve months ADIL reported a non-GAAP Earnings per Share(EPS) of -0.95. The EPS increased by 67.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -142.26% | ||
| ROE | -178.73% | ||
| Debt/Equity | 0 |
ADIL Forecast & Estimates
9 analysts have analysed ADIL and the average price target is 2.21 USD. This implies a price increase of 937.57% is expected in the next year compared to the current price of 0.213.
ADIL Ownership
About ADIL
Company Profile
Adial Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment or prevention of addiction and related disorders. The company is headquartered in Charlottesville, Virginia and currently employs 5 full-time employees. The company went IPO on 2018-07-27. The firm is focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD pivotal Phase III clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.
Company Info
ADIAL PHARMACEUTICALS INC
1180 Seminole Trail, Suite 495
Charlottesville VIRGINIA 22901 US
CEO: William B. Stilley
Employees: 5
Phone: 14344229800
ADIAL PHARMACEUTICALS INC / ADIL FAQ
What does ADIL do?
Adial Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment or prevention of addiction and related disorders. The company is headquartered in Charlottesville, Virginia and currently employs 5 full-time employees. The company went IPO on 2018-07-27. The firm is focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD pivotal Phase III clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.
Can you provide the latest stock price for ADIAL PHARMACEUTICALS INC?
The current stock price of ADIL is 0.213 USD. The price decreased by -0.28% in the last trading session.
Does ADIAL PHARMACEUTICALS INC pay dividends?
ADIL does not pay a dividend.
What is the ChartMill rating of ADIAL PHARMACEUTICALS INC stock?
ADIL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for ADIL stock?
9 analysts have analysed ADIL and the average price target is 2.21 USD. This implies a price increase of 937.57% is expected in the next year compared to the current price of 0.213.
What is the GICS sector and industry of ADIL stock?
ADIAL PHARMACEUTICALS INC (ADIL) operates in the Health Care sector and the Pharmaceuticals industry.